Clostridium Butyricum

(Total 1 Products)

Effective beneficial microorganism for human C. butyricum

USD 42 ~ USD 50

Brand:N
Model No:CB01
Transportation:Express,Air,Land,Ocean
Packaging:Bagged/ Bottled/ boxed
Supply Ability:5,000KG/G
Place of Origin:CN
Productivity:5,000KG/G

Introduction It is a strictly anaerobic, Gram-positive, spore-forming bacillus named for its capacity to produce high amounts of butyric acid. It was first isolated from pig intestines in 1880. Since then, several strains of C. butyricum have been...

Contact Now

Effective beneficial microorganism for human C. butyricum

Effective beneficial microorganism for human C. butyricum
USD 42 ~ USD 50

Contact Now

C. butyricum, a butyrate-producing, spore-forming anaerobic bacterium, is found in a wide variety of environments, including soil, cultured milk products, and vegetables. It is also present in the human gut: it is detected in 10–20% of the adult human population and is often one of the earliest colonizers in infants. In the human gut, where it is considered a ‘symbiont (living together with the host), C. butyricum has a fermentative lifestyle and can consume undigested dietary fibers and generate short-chain fatty acids (SCFAs), specifically butyrate and acetate. Butyrate is one of the dominant fermentation end-products and is produced by C. butyricum via the butyrate kinase (buk) pathway. SCFAs produced by microbial organisms in the colon are known to have myriad and important effects on host health, including modulating intestinal immune homeostasis, improving gastrointestinal barrier function, and alleviating inflammation. As such, butyrate-producing organisms like C. butyricum have become attractive candidates to test for beneficial effects in a host. Genomic analyses are increasingly identifying novel bacterial strains with health-promoting potential that are distinct from classic Probiotics (Lactobacilli and Bifidobacteria).

C. butyricum is a species that encompasses various known strains, some of which have genes equipping them to produce toxins. However, genomic analyses confirm that other strains do not have these genes nor other markers of pathogenesis potential, and that these nonpathogenic strains have excellent potential to benefit host health through several mechanisms. Certain strains of C. butyricum have been used as a probiotic for decades. Strain MIYAIRI 588 (or MIYARI 588; CBM 588), first isolated from the feces of a healthy human by Dr. Chikaji Miyairi in 1933, and later from soil in 1963, is a commercially-available, over-the-counter probiotic widely used in Japan, Korea, and China for the treatment of (antimicrobial-associated) diarrhea. Strain CBM 588 is also authorized under the regulation of the European Parliament and of the Council as a novel food ingredient. Its widespread use is enabled by its safe, nonpathogenic and nontoxic profile: studies have shown that it is sensitive to antibiotics, devoid of pathogenic markers, and lacks clostridial toxin genes.

MAIN PRODUCT

Probiotics Powder improves intestinal motility, diarrhea, and astriction relief; enhances digestion and absorption; relieves chronic gastritis and intestinal inflammation; and relieves allergic symptoms.

Probiotics Capsule

Probiotics Tablets

Probiotics Powder

About Biodep

Jiangsu Biodep Biotechnology Co., Ltd. Focuses on biotechnology research and applications, headquartered at the national high-tech development zone in Jiangyin, Jiangsu Province. Company's products are applied in foodstuff, healthy food, cosmetics, environmental treatment, modern agriculture and other fields. With extensive experience in biotechnology and functional food formulations, we offer our customers scientific and effective manufacturing solutions. The main products are high - activity Probiotics powder, probiotics capsules, probiotics tablets.There are many subsidiaries, Including Jiangsu New-bio Biotechnology Co., Ltd. Is a wholly-owned holding company of Jiangsu Biodep Biotechnology Co., Ltd., Probiotic powder is produced by Jiangsu Biodep Biotechnology Co., Ltd., and Jiangsu Biodep Biotechnology Co., Ltd. exports Probiotics Powder as a trader.The entity is developing special functional probiotics in the fields of Alzheimer's, diabetes, depression and spinal injury in association with Woodhead Medical College, Rutgers University and the University of Queensland. Those probiotics are already being used in FSMP (Foods for Special Medical Purpose). The company holds a stake in Probiotics Australia Pty Ltd, an Australian probiotics manufacturer.At present, the company have obtained NSF-GMP certification, NOP certification, HACCP certification, ISO22000 certification, ISO9000 certification, KOSHER certification, HALAL certification.The company set the value as "Biotechnology shapes our future", depends on biotechnology as the driving force for development, and strive to create a healthy lifestyle.

Certificate